05.22.26 -- Why Your MES RFP Is Failing Before It Starts

Explore the current challenges of developing gene therapies, the potential of Organ-on-a-Chip technology, the future of gene therapy, and more.

Review the role of solid form screening and PBPK modeling to enable accelerated timelines desirable in early-phase drug development, as well as formulation maps for ASDs and key criteria for salt screening.

Driven by GLP-1 success and rising obesity rates, R&D investment in metabolic disease therapies now rivals oncology, demanding rapid development to overcome market challenges.

A pioneering perspective uncovers how new scientific thinking, physics‑based insights, and bold leadership are expanding and opening therapeutic paths once thought impossible.

Overcome the complex ADME and DDI challenges of antibody–drug conjugates with tailored, data-driven strategies that accelerate development and support regulatory success.

Discover how early developability assessments and a quality-by-design approach can streamline formulation, reduce risk, and accelerate your path to successful, cost-effective drug development.

Streamlined collaboration and unified quality systems are helping CDMOs cut review times. See how connected workflows improve compliance and efficiency for faster delivery of life-changing treatments.

Streamline your operations within a single framework with advanced checkweighers that enhance industrial quality control with precise weight measurements and regulatory compliance.

Sterile manufacturing remains vital, with resilient supply chains preventing shortages. Industry and regulators prioritize integrity as demand surges, making it the fastest-growing pharmaceutical segment.

Schedule‑based maintenance supports compliance but misses risk. Find out how GMP manufacturers are moving toward condition‑based and predictive strategies to modernize asset management.

Examine how adding a traceless tag enables streamlined affinity purification for recombinant proteins, and how this approach compares with a conventional process in development time, recovery, and purity.

Learn why single-use cold-chain containers made with polytetrafluoroethylene fluoropolymers may be less susceptible to failure and breakage at cold temperatures.

Read more about how holistic training and validation services help manufacturers navigate complex regulatory demands and achieve operational readiness faster.

Stop treating contamination control as a late-stage detail. Reveal how making early, intentional design choices prevents startup delays and ensures your new cleanroom is ready for inspection.

Leverage mechanistic, material-sparing formulation strategies to enhance bioavailability and accelerate development of challenging bRo5 small molecules, even with limited resources.

Antibody–drug conjugates combine mAbs, linkers, and potent cytotoxins, requiring highly sensitive analytics and flexible platforms to manage manufacturing complexity and contamination risks.